advertisement
Abstract #72852 Published in IGR 18-4
Novel Regulatory Mechanisms for the SoxC Transcriptional Network Required for Visual Pathway Development
Chang KC; Hertz J; Zhang X; Jin XL; Shaw P; Derosa BA; Li JY; Venugopalan P; Valenzuela DA; Patel RD; Russano KR; Alshamekh SA; Sun C; Tenerelli K; Li C; Velmeshev D; Cheng Y; Boyce TM; Dreyfuss A; Uddin MS; Muller KJ; Dykxhoorn DM; Goldberg JLJournal of Neuroscience 2017; 37: 4967-4981
What pathways specify retinal ganglion cell (RGC) fate in the developing retina? Here we report on mechanisms by which a molecular pathway involving Sox4/Sox11 is required for RGC differentiation and for optic nerve formation in mice in vivo, and is sufficient to differentiate human induced pluripotent stem cells into electrophysiologically active RGCs. These data place Sox4 downstream of RE1 silencing transcription factor in regulating RGC fate, and further describe a newly identified, Sox4-regulated site for post-translational modification with small ubiquitin-related modifier (SUMOylation) in Sox11, which suppresses Sox11's nuclear localization and its ability to promote RGC differentiation, providing a mechanism for the SoxC familial compensation observed here and elsewhere in the nervous system. These data define novel regulatory mechanisms for this SoxC molecular network, and suggest pro-RGC molecular approaches for cell replacement-based therapies for glaucoma and other optic neuropathies.SIGNIFICANCE STATEMENT Glaucoma is the most common cause of blindness worldwide and, along with other optic neuropathies, is characterized by loss of retinal ganglion cells (RGCs). Unfortunately, vision and RGC loss are irreversible, and lead to bilateral blindness in ∼14% of all diagnosed patients. Differentiated and transplanted RGC-like cells derived from stem cells have the potential to replace neurons that have already been lost and thereby to restore visual function. These data uncover new mechanisms of retinal progenitor cell (RPC)-to-RGC and human stem cell-to-RGC fate specification, and take a significant step toward understanding neuronal and retinal development and ultimately cell-transplant therapy.
Department of Ophthalmology, Stanford University, Palo Alto, California 94304, kunche@stanford.edu.
Full articleClassification:
2.17 Stem cells (Part of: 2 Anatomical structures in glaucoma)
11.8 Neuroprotection (Part of: 11 Medical treatment)
5.1 Rodent (Part of: 5 Experimental glaucoma; animal models)
